# Abbott Laboratories (ABT.US)

Canonical: https://gigainvestors.com/s/ABT

Analysis as of: 2026-10-16T07:26:08.905Z. Financial observations: FY1996–FY2026.

Listing currency: USD. Reporting currency: USD.

## Verdict

A wonderful business at too high a price

Quality tests for Buy: pass (profit record: pass; earnings resilience is evidence only). Published buy qualification: no.

Share price: $104.68 per share; close as of 2026-10-15.

Estimated value: low $59.48 per share, central $67.31 per share, high $77.73 per share. Buy at or below the central value $67.31 per share. Valuation as of 2026-10-16T07:26:08.905Z; scenarios are not confidence intervals.

Expected annual return: 7.4% at the stated quote. About 7.4% a year at today's price (required return 10.0%). required return 10.0% a year (10% floor; US 10-year bond 5.1% + 4 points).

## Checklist

### understandable: pass

- 1 revenue decline in the last 10 years (informational)

- Financial history: 10 years

- Years with declining revenue: 1

- Years with a net loss: 0

- Operating margin variation: 0.24×

Chart: Operating margin; fiscal year observations.

- FY2017: 0.07×

- FY2018: 0.13×

- FY2019: 0.14×

- FY2020: 0.15×

- FY2021: 0.21×

- FY2022: 0.19×

- FY2023: 0.16×

- FY2024: 0.16×

- FY2025: 0.18×

- LTM to Mar 2026: 0.18×

### moat: pass

- ROIC, median of available years: 19.8%

- ROIC, second-lowest year: 13.7%

- Typical minus recent gross margin: 0.6 pp

- Typical gross margin (annual median): 51.4%

- Recent gross margin (lower of latest and 3-year median): 50.8%

- Years with nonpositive capital: 0

- Capital spending / revenue: 5.0%

- ROIC including acquisitions, ten-year median: 12.4%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2016: 15.2%

- FY2017: 5.1%

- FY2018: 13.7%

- FY2019: 18.2%

- FY2020: 21.9%

- FY2021: 36.7%

- FY2022: 32.2%

- FY2023: 23.5%

- FY2024: 21.4%

- FY2025: 18.1%

### economics: pass

- Owner earnings / net income, 5-yr: 1.14×

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: $44B

- Net income, five-year total: $39B

- Return on incremental invested capital: >100%

- Working capital / revenue, annual change: 0.2 pp

- Working capital / revenue, change between three-year averages: 1.3 pp

- Working capital / revenue, final three-year average: 22.5%

Chart: Annual owner cash / profit; fiscal year observations.

- FY2022: 1.21×

- FY2023: 1.18×

- FY2024: 1.08×

- FY2025: 1.14×

- LTM to Mar 2026: 1.16×

### management: pass

- Historical market-dollar context (not the management verdict): 2016 to 2025 (9 years)

- buybacks leaned toward cheaper years (informational)

- ROIC first 3 years vs last 3 years: 13.7% vs 21.4%

- Per-share earnings: 0.94 to 3.73 (three-year endpoint medians)

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 10-year annual growth: 1.5%

- Ordinary dilution, 5-year annual growth: -0.4%

- Market cap gain: $162B

- Cumulative retained earnings: $24B

- Diluted shares, 10-year annual growth: 1.5%

- Diluted shares, 5-year annual growth: -0.4%

- $1 test, starting fiscal year: FY2016

- $1 test, ending fiscal year: FY2025

- Per-share value growth: 18.7%

- Per-share value change: $2.79

- Per-share value, starting three-year median: $0.94

- Per-share value, ending three-year median: $3.73

- Buybacks concentrated in cheaper years (correlation): 0.37

- Average buyback yield: 0.7%

- Buyback history: 10 years

- Debt-funded buybacks: No

- Acquisition spending: $33B

- Cumulative net income, 10 years: $52B

- ROIC, first three-year median: 13.7%

- ROIC, last three-year median: 21.4%

Chart: Earnings per share; fiscal year observations.

- FY2016: $0.94

- FY2017: $0.27

- FY2018: $1.34

- FY2019: $2.07

- FY2020: $2.52

- FY2021: $3.95

- FY2022: $3.93

- FY2023: $3.27

- FY2024: $7.67

- FY2025: $3.73

### accounting: pass

- Sloan accruals: -3.5%

- Receivables to sales index (DSRI): 1.08×

- Restructuring years, last five: 0

- Stock compensation / operating cash flow: 6.9%

- Earnings backed by cash: Yes

- Operating cash / earnings: 1.47×

- Accounting red flags: 0

- Goodwill and intangibles / equity: 0.57×

Chart: Sloan accruals; fiscal year observations.

- FY2016: -3.3%

- FY2017: -6.7%

- FY2018: -5.9%

- FY2019: -3.6%

- FY2020: -4.7%

- FY2021: -4.6%

- FY2022: -3.6%

- FY2023: -2.1%

- FY2024: 5.9%

- FY2025: -3.5%

## Holders

- [David Hoeft](https://gigainvestors.com/DAC): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Thomas Russo](https://gigainvestors.com/GR): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Allen Bond](https://gigainvestors.com/JIM): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [David Katz](https://gigainvestors.com/MAVFX): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Andrew Adams](https://gigainvestors.com/MPF): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Mason Hawkins](https://gigainvestors.com/SE): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Dan Davidowitz](https://gigainvestors.com/pcm): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 26% since Dec 2021 · "Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist" (finance.yahoo.com, Sep 2026) · sales +1.8%

Story as of 2026-10-16T09:58:13.129Z; price observation 2026-10-15.

Price needs cash profits to grow 6.6% a year for ten years

- 2025-07-18: Abbott Labs stock falls 8% as China headwinds prompt guidance cut ([investing.com](https://www.investing.com/news/analyst-ratings/abbott-labs-stock-falls-8-as-china-headwinds-prompt-guidance-cut-93CH-4141751))

- 2025-10-15: Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. ([finance.yahoo.com](https://finance.yahoo.com/m/a1914f45-650e-36af-9e52-cb88c10d2594/abbott-stock-drops-despite.html))

- 2026-01-22: Abbott Laboratories Raised Prices, Prompting Sales Slump ([finance.yahoo.com](https://finance.yahoo.com/m/d97bb269-347f-34ed-ba64-32f6f07cf0d8/abbott-laboratories-raised.html))

- 2026-04-16: Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Biting. ([finance.yahoo.com](https://finance.yahoo.com/m/c42b4049-f158-3a12-8ffa-4b61a80701d8/abbott-stock-tumbles-on.html))

- 2026-07-16: Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/abbott-abt-lifts-2026-eps-201437790.html))

- 2026-09-24: Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-facing-segment-131040100.html))

### Sales · FY2025–2026

sales +1.8%; source https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm; observed 2026-02-20.

- FY2017: $27B 

- FY2018: $31B 

- FY2019: $32B 

- FY2020: $35B 

- FY2021: $43B 

- FY2022: $44B 

- FY2023: $40B 

- FY2024: $42B 

- FY2025: $44B 

- FY2026: $45B 

### Gross margin · FY2025

gross margin 55.5%; source https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm; observed 2026-02-20.

- FY2016: 53.9% 

- FY2017: 47.7% 

- FY2018: 51.7% 

- FY2019: 52.3% 

- FY2020: 50.2% 

- FY2021: 53.9% 

- FY2022: 51.1% 

- FY2023: 50.0% 

- FY2024: 50.8% 

- FY2025: 55.5% 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in medical devices; annual sales are USD 44.3 billion.

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); FY2025: revenue 44328000000; grossProfit 24607000000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); ABT.US: Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

### Why customers stay

Margins ranged from 50% to 55.5% during 2023–25; it earns 19.8% on its capital.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2023: grossProfit / revenue = 50%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2024: grossProfit / revenue = 50.8%.

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); FY2025: grossProfit / revenue = 55.5%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); 10-year return on capital observations [[2016,0.1519472168305549],[2017,0.05088325195506332],[2018,0.1372673355186408],[2019,0.1816835066403554],[2020,0.21860650981449767],[2021,0.3672502236884185],[2022,0.3221965137466428],[2023,0.23498325897243835],[2024,0.2141915641476274],[2025,0.18121977158208713]]; median 0.1979375353939914. ROIC follows the displayed moat series; financial companies use return on tangible equity.

### Can it raise prices

In the United States and other countries, Abbott’s businesses have experienced downward pressure on certain product pricing.

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); Both in the U.S. and internationally, government authorities may enact changes in regulatory requirements, make legislative or administrative reforms to existing reimbursement programs, make adverse decisions relating to Abbott’s products’ coverage or reimbursement, or make changes to patient ac nt efforts that could cause a reduction in future revenues and operating earnings. In the United States and other countries, Abbott’s businesses have experienced downward pressure on certain product pricing. Cost containment efforts by governments and private organizations are described in greater detail in the section captioned “Regulation.” To the extent these cost containment efforts are not offset by greater patient access to healthcare or other factors, Abbott’s future revenues and operating earnings will be reduced.

### Where the cash goes

Paid dividends in 10 of 10 years; bought back USD 893 million of shares.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2016: growth capex 0; upkeep 1121000000; owner earnings 1632000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2017: growth capex 0; upkeep 1135000000; owner earnings 2363000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2018: growth capex 0; upkeep 1394000000; owner earnings 4252000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2019: growth capex 0; upkeep 1638000000; owner earnings 5063000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2020: growth capex 0; upkeep 2177000000; owner earnings 5645000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2021: growth capex 0; upkeep 1885000000; owner earnings 8724000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2022: growth capex 0; upkeep 1777000000; owner earnings 8423000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2023: growth capex 0; upkeep 2202000000; owner earnings 6764000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); FY2024: growth capex 0; upkeep 2207000000; owner earnings 14413000000. Growth capex / owner earnings = 0.

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); FY2025: growth capex 0; upkeep 2171000000; owner earnings 7469000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); Dividend observations: [[2016,1539000000],[2017,1849000000],[2018,1974000000],[2019,2270000000],[2020,2560000000],[2021,3202000000],[2022,3309000000],[2023,3556000000],[2024,3836000000],[2025,4116000000]]. Zero only counted when supported by a complete cash-flow statement.

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); FY2025: cash repurchases 893000000 USD.

### Are managers owners

Insiders own 0.5% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); ABT.US SharesStats.PercentInsiders = 0.492 percentage points; cache date 2026-10-16.

### What could break it

"Fluctuation in foreign currency exchange rates has adversely affected" (SEC filing, Feb 2026)

- Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm (filed 2026-02-20); Fluctuation in foreign currency exchange rates has adversely affected

### What the price says

The price assumes cash profits grow 6.6% yearly over ten years; actual growth was 3%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-20); Ten-year compound average after fade. Initial solved rate 0.0819611652574691. Price 104.68; FX 1; discount 0.1; same standard ten-year fade to terminal 0.03. FY2015 owner earnings/share 3.1772908366533863 → FY2025 4.272883295194508. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2016-10: $39.24 per share

- 2016-11: $38.07 per share

- 2016-12: $38.41 per share

- 2017-01: $41.77 per share

- 2017-02: $45.08 per share

- 2017-03: $44.41 per share

- 2017-04: $43.64 per share

- 2017-05: $45.66 per share

- 2017-06: $48.61 per share

- 2017-07: $49.18 per share

- 2017-08: $50.94 per share

- 2017-09: $53.36 per share

- 2017-10: $54.23 per share

- 2017-11: $56.37 per share

- 2017-12: $57.07 per share

- 2018-01: $62.16 per share

- 2018-02: $60.33 per share

- 2018-03: $59.92 per share

- 2018-04: $58.13 per share

- 2018-05: $61.53 per share

- 2018-06: $60.99 per share

- 2018-07: $65.54 per share

- 2018-08: $66.84 per share

- 2018-09: $73.36 per share

- 2018-10: $68.94 per share

- 2018-11: $74.05 per share

- 2018-12: $72.33 per share

- 2019-01: $72.98 per share

- 2019-02: $77.62 per share

- 2019-03: $79.94 per share

- 2019-04: $79.56 per share

- 2019-05: $76.13 per share

- 2019-06: $84.10 per share

- 2019-07: $87.10 per share

- 2019-08: $85.32 per share

- 2019-09: $83.67 per share

- 2019-10: $83.61 per share

- 2019-11: $85.45 per share

- 2019-12: $86.86 per share

- 2020-01: $87.14 per share

- 2020-02: $77.03 per share

- 2020-03: $78.91 per share

- 2020-04: $92.09 per share

- 2020-05: $94.92 per share

- 2020-06: $91.43 per share

- 2020-07: $100.64 per share

- 2020-08: $109.47 per share

- 2020-09: $108.83 per share

- 2020-10: $105.11 per share

- 2020-11: $108.22 per share

- 2020-12: $109.49 per share

- 2021-01: $123.59 per share

- 2021-02: $119.78 per share

- 2021-03: $119.84 per share

- 2021-04: $120.08 per share

- 2021-05: $116.65 per share

- 2021-06: $115.93 per share

- 2021-07: $120.98 per share

- 2021-08: $126.37 per share

- 2021-09: $118.13 per share

- 2021-10: $128.89 per share

- 2021-11: $125.77 per share

- 2021-12: $140.74 per share

- 2022-01: $127.46 per share

- 2022-02: $120.62 per share

- 2022-03: $118.36 per share

- 2022-04: $113.50 per share

- 2022-05: $117.46 per share

- 2022-06: $108.65 per share

- 2022-07: $108.84 per share

- 2022-08: $102.65 per share

- 2022-09: $96.76 per share

- 2022-10: $98.94 per share

- 2022-11: $107.58 per share

- 2022-12: $109.79 per share

- 2023-01: $110.55 per share

- 2023-02: $101.72 per share

- 2023-03: $101.26 per share

- 2023-04: $110.47 per share

- 2023-05: $102.00 per share

- 2023-06: $109.02 per share

- 2023-07: $111.33 per share

- 2023-08: $102.90 per share

- 2023-09: $96.85 per share

- 2023-10: $94.55 per share

- 2023-11: $104.29 per share

- 2023-12: $110.07 per share

- 2024-01: $113.15 per share

- 2024-02: $118.64 per share

- 2024-03: $113.66 per share

- 2024-04: $105.97 per share

- 2024-05: $102.19 per share

- 2024-06: $103.91 per share

- 2024-07: $105.94 per share

- 2024-08: $113.27 per share

- 2024-09: $114.01 per share

- 2024-10: $113.37 per share

- 2024-11: $118.77 per share

- 2024-12: $113.11 per share

- 2025-01: $127.93 per share

- 2025-02: $138.01 per share

- 2025-03: $132.65 per share

- 2025-04: $130.75 per share

- 2025-05: $133.58 per share

- 2025-06: $136.01 per share

- 2025-07: $126.19 per share

- 2025-08: $132.66 per share

- 2025-09: $133.94 per share

- 2025-10: $123.62 per share

- 2025-11: $128.90 per share

- 2025-12: $125.29 per share

- 2026-01: $109.30 per share

- 2026-02: $116.35 per share

- 2026-03: $102.67 per share

- 2026-04: $90.79 per share

- 2026-05: $85.60 per share

- 2026-06: $90.74 per share

- 2026-07: $105.70 per share

- 2026-08: $110.36 per share

- 2026-09: $98.83 per share

- 2026-10: $102.61 per share

## Annual estimated value (USD per share)

- FY2016: low $34.54 per share, central $37.59 per share, high $41.66 per share

- FY2017: low $28.47 per share, central $31.68 per share, high $35.96 per share

- FY2018: low $27.66 per share, central $31.20 per share, high $35.92 per share

- FY2019: low $29.19 per share, central $32.95 per share, high $37.94 per share

- FY2020: low $33.07 per share, central $37.13 per share, high $42.53 per share

- FY2021: low $47.01 per share, central $52.77 per share, high $60.44 per share

- FY2022: low $49.39 per share, central $55.47 per share, high $63.57 per share

- FY2023: low $45.97 per share, central $51.80 per share, high $59.56 per share

- FY2024: low $54.69 per share, central $61.67 per share, high $70.96 per share

- FY2025: low $58.09 per share, central $65.46 per share, high $75.28 per share

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

Prior published observations retained from 2026-10-15T06:31:43.912Z where newer inputs omit a numeric field or fiscal period.

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm); period 2025-12-31, filed 2026-02-20.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.

## Reported holder observations

- [David Hoeft](https://gigainvestors.com/DAC): 17,324 ABT shares; USD 1,572,000 reported position value; 0% of portfolio; hold; quarter 2026 Q2.
- [Thomas Russo](https://gigainvestors.com/GR): 11,510 ABT shares; USD 1,044,000 reported position value; 0.01% of portfolio; hold; quarter 2026 Q2.
- [Allen Bond](https://gigainvestors.com/JIM): 885,262 ABT shares; USD 80,329,000 reported position value; 1.95% of portfolio; reduce; quarter 2026 Q2.
- [David Katz](https://gigainvestors.com/MAVFX): 52,805 ABT shares; USD 5,219,000 reported position value; 0.43% of portfolio; add; quarter 2026 Q3.
- [Andrew Adams](https://gigainvestors.com/MPF): 729,358 ABT shares; USD 66,182,000 reported position value; 0.61% of portfolio; add; quarter 2026 Q2.
- [Mason Hawkins](https://gigainvestors.com/SE): 840,747 ABT shares; USD 76,289,000 reported position value; 3.98% of portfolio; new; quarter 2026 Q2.
- [Dan Davidowitz](https://gigainvestors.com/pcm): 3,156 ABT shares; USD 286,000 reported position value; 0% of portfolio; reduce; quarter 2026 Q2.

# ABT — Abbott Labs

Held by 1 investor · USD 5,219,000 total · 2026 Q3 · reported price USD 98.84 (split-adjusted).
Page: https://gigainvestors.com/s/ABT

## Holders (2026 Q3)

| Investor | Value | % of their portfolio | This quarter |
|---|---:|---:|---|
| David Katz (https://gigainvestors.com/MAVFX) | USD 5,219,000 | 0.4% | add +11.73% |

## Total held by quarter

- 2007 Q2: USD 185,823,855 · 1 holder · USD 53.55
- 2007 Q3: USD 186,066,762 · 1 holder · USD 53.62
- 2007 Q4: USD 194,846,115 · 1 holder · USD 56.15
- 2008 Q1: USD 191,376,015 · 1 holder · USD 55.15
- 2008 Q2: USD 183,811,197 · 1 holder · USD 52.97
- 2008 Q3: USD 199,808,358 · 1 holder · USD 57.58
- 2008 Q4: USD 204,823,706 · 2 holders · USD 53.37
- 2009 Q1: USD 182,612,581 · 2 holders · USD 47.70
- 2009 Q2: USD 21,643,386 · 1 holder · USD 47.04
- 2009 Q3: USD 27,916,416 · 1 holder · USD 49.47
- 2009 Q4: USD 19,554,368 · 1 holder · USD 53.99
- 2010 Q1: USD 22,670,575 · 1 holder · USD 52.68
- 2010 Q2: USD 20,193,523 · 1 holder · USD 46.78
- 2010 Q3: USD 22,307,525 · 1 holder · USD 52.24
- 2010 Q4: USD 20,688,496 · 1 holder · USD 47.91
- 2011 Q1: USD 21,412,532 · 1 holder · USD 49.05
- 2011 Q2: USD 22,876,282 · 1 holder · USD 52.62
- 2011 Q3: USD 21,743,552 · 1 holder · USD 51.14
- 2011 Q4: USD 21,530,073 · 1 holder · USD 56.23
- 2012 Q1: USD 22,649,903 · 1 holder · USD 61.29
- 2012 Q2: USD 22,896,907 · 1 holder · USD 64.47
- 2012 Q3: USD 7,167,948 · 1 holder · USD 68.56
- 2012 Q4: USD 5,849,150 · 1 holder · USD 65.50
- 2013 Q1: USD 3,097,564 · 1 holder · USD 35.32
- 2013 Q2: USD 3,010,249 · 1 holder · USD 34.88
- 2013 Q3: USD 2,871,035 · 1 holder · USD 33.19
- 2013 Q4: USD 3,315,660 · 1 holder · USD 38.33
- 2014 Q1: USD 3,331,231 · 1 holder · USD 38.51
- 2014 Q2: USD 3,537,973 · 1 holder · USD 40.90
- 2014 Q3: USD 3,597,660 · 1 holder · USD 41.59
- 2014 Q4: USD 3,844,708 · 1 holder · USD 45.02
- 2015 Q1: USD 3,956,582 · 1 holder · USD 46.33
- 2015 Q2: USD 4,190,578 · 1 holder · USD 49.07
- 2015 Q3: USD 3,434,788 · 1 holder · USD 40.22
- 2015 Q4: USD 3,835,314 · 1 holder · USD 44.91
- 2016 Q1: USD 852,924 · 1 holder · USD 41.81
- 2016 Q2: USD 645,012 · 1 holder · USD 39.33
- 2016 Q3: USD 694,048 · 1 holder · USD 42.32
- 2016 Q4: USD 629,924 · 1 holder · USD 38.41
- 2017 Q1: USD 727,996 · 1 holder · USD 44.39
- 2017 Q2: USD 806,926 · 1 holder · USD 48.61
- 2017 Q3: USD 879,945 · 1 holder · USD 53.33
- 2017 Q4: USD 729,984 · 1 holder · USD 57.03
- 2018 Q1: USD 766,976 · 1 holder · USD 59.92
- 2018 Q2: USD 851,002 · 1 holder · USD 60.96
- 2018 Q3: USD 9,897,372 · 2 holders · USD 73.36
- 2018 Q4: USD 9,693,729 · 2 holders · USD 72.35
- 2019 Q1: USD 10,473,378 · 2 holders · USD 79.94
- 2019 Q2: USD 10,916,705 · 2 holders · USD 84.10
- 2019 Q3: USD 20,801,710 · 3 holders · USD 83.67
- 2019 Q4: USD 786,181,881 · 3 holders · USD 86.86
- 2020 Q1: USD 1,324,549,289 · 3 holders · USD 78.91
- 2020 Q2: USD 1,722,338,462 · 3 holders · USD 91.43
- 2020 Q3: USD 2,125,008,681 · 3 holders · USD 108.83
- 2020 Q4: USD 2,256,983,601 · 3 holders · USD 109.49
- 2021 Q1: USD 2,496,563,564 · 3 holders · USD 119.84
- 2021 Q2: USD 2,562,603,892 · 3 holders · USD 115.93
- 2021 Q3: USD 2,614,511,752 · 3 holders · USD 118.13
- 2021 Q4: USD 3,190,668,776 · 3 holders · USD 140.74
- 2022 Q1: USD 2,668,145,573 · 3 holders · USD 118.36
- 2022 Q2: USD 1,683,128,957 · 3 holders · USD 108.65
- 2022 Q3: USD 1,529,553,860 · 3 holders · USD 96.76
- 2022 Q4: USD 1,618,192,094 · 4 holders · USD 109.81
- 2023 Q1: USD 1,454,814,629 · 4 holders · USD 101.26
- 2023 Q2: USD 1,524,088,298 · 4 holders · USD 109.02
- 2023 Q3: USD 1,316,965,830 · 4 holders · USD 96.85
- 2023 Q4: USD 1,497,700,537 · 4 holders · USD 110.08
- 2024 Q1: USD 2,056,487,422 · 7 holders · USD 113.66
- 2024 Q2: USD 1,769,753,175 · 6 holders · USD 103.91
- 2024 Q3: USD 1,772,365,673 · 7 holders · USD 114.01
- 2024 Q4: USD 1,614,130,077 · 7 holders · USD 113.12
- 2025 Q1: USD 1,830,435,692 · 6 holders · USD 132.65
- 2025 Q2: USD 1,901,787,857 · 7 holders · USD 136.01
- 2025 Q3: USD 1,417,834,730 · 7 holders · USD 133.94
- 2025 Q4: USD 823,914,349 · 7 holders · USD 125.29
- 2026 Q1: USD 231,185,292 · 5 holders · USD 102.67
- 2026 Q2: USD 229,991,027 · 7 holders · USD 90.74
- 2026 Q3: USD 5,219,000 · 1 holder · USD 98.84